Evidence map›Paper›PMID 37034605›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Viral and Host Mediators of Non-Suppressible HIV-1 Viremia.

Abbas Mohammadi, Behzad Etemad, Xin Zhang, Yijia Li, Gregory J Bedwell, Radwa Sharaf, Autumn Kittilson, Meghan Melberg, Colline Wong, Jesse Fajnzylber and 26 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors at 8 institutions in 2 countries.

Abbas MohammadiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Behzad EtemadBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Xin ZhangBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Yijia LiUniversity of Pittsburgh, Pittsburgh, PA, USA.
Gregory J BedwellDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Radwa SharafBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Autumn KittilsonBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Meghan MelbergBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Colline WongBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jesse FajnzylberBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Daniel P WorrallRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Alex RosenthalBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Hannah JordanBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nikolaus JilgBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Clarety KasekeRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Francoise GiguelMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Xiaodong LianMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Rinki DeoBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Elisabeth GillespieBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Rida ChishtiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Sara AbrhaBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Taylor AdamsBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Abigail SiagianBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Peter L AndersonDivision of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Steven G DeeksDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.
Michael M LedermanCenter for AIDS Research, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Sigal YawetzBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Daniel R KuritzkesBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Mathias D LichterfeldMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Athe TsibrisBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Mary CarringtonRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Jose R Castillo-MancillaDivision of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Alan N EngelmanDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Gaurav D GaihaRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Brigham and Women's Hospital · USHarvard University · USRagon Institute of MGH, MIT and Harvard · USUniversity of Colorado Anschutz Medical Campus · USSimon Fraser University · CAUniversity Hospitals of Cleveland · USUniversity of California, San Francisco · USUniversity of Pittsburgh · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Project 3. IntegrationU54AI170791 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Juan Roberto Perilla Jimenez · 2022 to 2026
$30.6M
Effects of genetic polymorphism in MHC, KIR, and related loci on human diseaseZIABC010791 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$18.2M
Biochemical Mechanism of HIV DNA IntegrationR37AI039394 · NIAID · DANA-FARBER CANCER INST · PI Alan N. Engelman · 2010 to 2026
$10.2M
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 3P01AI169768 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Ya-Chi Ho, Jonathan Li · 2022 to 2026
$10.1M
Viral and Immune Determinants of HIV ReboundR56AI125109 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LI, JONATHAN · 2016 to 2016
$897k
NCI NIH HHS 75N91019D00024NIAID NIH HHS P01 AI169768NIAID NIH HHS P30 AI060354NIAID NIH HHS R37 AI039394NIAID NIH HHS R56 AI125109NIAID NIH HHS U54 AI170791NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

Non-suppressible HIV-1 viremia (NSV) can occur in persons with HIV despite adherence to combination antiretroviral therapy (ART) and in the absence of significant drug resistance. Here, we show that plasma NSV sequences are comprised primarily of large clones without evidence of viral evolution over time. We defined proviruses that contribute to plasma viremia as "producer", and those that did not as "non-producer". Compared to ART-suppressed individuals, NSV participants had a significantly larger producer reservoir. Producer proviruses were enriched in chromosome 19 and in proximity to the activating H3K36me3 epigenetic mark. CD4

Indexed as

CD8 immune responseHIVintegrationnon-suppressible viremiapersistent low-level viremiaproducer provirus

Identifiers

PMID37034605
PMCPMC10081408
OpenAlexW4361864049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.